COMPOSITIONS FOR T-CELL THERAPY WITH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF Russian patent published in 2024 - IPC A61K9/00 A61K35/17 A61K39/395 A61K47/54 A61P31/00 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: group of inventions relates to use of an amphiphilic ligand conjugate for activating, building up or increasing proliferation of T-cells of a chimeric antigen receptor (CAR) in a subject, where the amphiphilic ligand conjugate contains: CAR ligand which binds to CAR expressed by said CAR-T cells, and a lipid functionally bound to the CAR ligand, where the lipid has a length of more than 12 hydrocarbon units, also relates to a method for activating, growing or increasing proliferation of CAR-T cells in patient, also relates to a method for reducing or reducing the size of a tumour or inhibiting tumour growth in a patient in need thereof, characterized by that the patient receives or has received a CAR-T cell therapy, also relates to a method of inducing an antitumour response in a patient with cancer, characterized by that the patient is receiving or has received a CAR-T cell therapy, also relates to a method of stimulating an immune response in a patient to a target cell population or a target tissue expressing an antigen, also relates to a method of treating a patient having a disease, disorder or condition associated with expression or overexpression of an antigen also relates to a kit for treating or delaying the progression of an oncological disease in an individual receiving CAR-T-cell therapy, and also relates to a kit for activating, building up or increasing proliferation of CAR-T-cells in an individual receiving CAR-T-cell therapy.

EFFECT: group of inventions provides treating or slowing down the progression of cancer in an individual receiving CAR-T cell therapy, provides an increase in chimeric antigen receptor (CAR) T cell proliferation in a subject, provides reducing or reducing the size of a tumour or inhibiting tumour growth in a subject, inducing an antitumour response, stimulating an immune response to a population of target cells or a target tissue expressing an antigen, in a subject or treating a subject having a disease, disorder or condition associated with expression or overexpression of an antigen.

95 cl, 7 ex, 39 dwg